- Home
- DMAC vs IDR Comparison
DMAC vs IDR Comparison
Compare DMAC & IDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- IDR
- Stock Information
- Founded
- DMAC 2000
- IDR 1996
- Country
- DMAC United States
- IDR United States
- Employees
- DMAC N/A
- IDR N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- IDR Precious Metals
- Sector
- DMAC Health Care
- IDR Basic Materials
- Exchange
- DMAC Nasdaq
- IDR Nasdaq
- Market Cap
- DMAC 178.0M
- IDR 154.1M
- IPO Year
- DMAC N/A
- IDR N/A
- Fundamental
- Price
- DMAC $3.76
- IDR $13.06
- Analyst Decision
- DMAC Strong Buy
- IDR Strong Buy
- Analyst Count
- DMAC 2
- IDR 1
- Target Price
- DMAC $8.00
- IDR $17.50
- AVG Volume (30 Days)
- DMAC 307.4K
- IDR 349.6K
- Earning Date
- DMAC 08-06-2025
- IDR 07-29-2025
- Dividend Yield
- DMAC N/A
- IDR N/A
- EPS Growth
- DMAC N/A
- IDR 144.40
- EPS
- DMAC N/A
- IDR 0.62
- Revenue
- DMAC N/A
- IDR $27,144,971.00
- Revenue This Year
- DMAC N/A
- IDR $9.76
- Revenue Next Year
- DMAC N/A
- IDR N/A
- P/E Ratio
- DMAC N/A
- IDR $21.09
- Revenue Growth
- DMAC N/A
- IDR 67.42
- 52 Week Low
- DMAC $2.80
- IDR $9.58
- 52 Week High
- DMAC $6.82
- IDR $19.75
- Technical
- Relative Strength Index (RSI)
- DMAC 47.18
- IDR 44.06
- Support Level
- DMAC $3.48
- IDR $12.40
- Resistance Level
- DMAC $3.99
- IDR $13.40
- Average True Range (ATR)
- DMAC 0.32
- IDR 0.56
- MACD
- DMAC -0.00
- IDR -0.06
- Stochastic Oscillator
- DMAC 41.01
- IDR 27.62
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.